A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: the comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYp
Mukhtar, Omar; Cheriyan, Joseph; Cockcroft, John R.; Collier, David; Coulson, James M.; Dasgupta, Indranil; Faconti, Luca; Glover, Mark; Heagerty, Anthony M.; Khong, Teck K.; Lip, Gregory Y.H.; Mander, Adrian P.; Marchong, Mellone N.; Martin, Una; McDonnell, Barry J.; McEniery, Carmel M.; Padmanabhan, Sandosh; Saxena, Manish; Sever, Peter J.; Shiel, Julian I.; Wych, Julie; Chowienczyk, Phil J.; Wilkinson, Ian B.
John R. Cockcroft
James M. Coulson
MARK GLOVER Mark.Glover@nottingham.ac.uk
Clinical Associate Professor
Anthony M. Heagerty
Teck K. Khong
Gregory Y.H. Lip
Adrian P. Mander
Mellone N. Marchong
Barry J. McDonnell
Carmel M. McEniery
Peter J. Sever
Julian I. Shiel
Phil J. Chowienczyk
Ian B. Wilkinson
BACKGROUND: Ethnicity, along with a variety of genetic and environmental factors, is thought to influence the efficacy of antihypertensive therapies. Current UK guidelines use a "black versus white" approach; in doing so, they ignore the United Kingdom's largest ethnic minority: Asians from South Asia.
STUDY DESIGN: The primary purpose of the AIM-HY INFORM trial is to identify potential differences in response to antihypertensive drugs used as mono- or dual therapy on the basis of self-defined ethnicity. A multicenter, prospective, open-label, randomized study with 2 parallel, independent trial arms (mono- and dual therapy), AIM-HY INFORM plans to enroll a total of 1,320 patients from across the United Kingdom. Those receiving monotherapy (n = 660) will enter a 3-treatment (amlodipine 10 mg od; lisinopril 20 mg od; chlorthalidone 25 mg od), 3-period crossover, lasting 24 weeks, whereas those receiving dual therapy (n = 660) will enter a 4-treatment (amlodipine 5 mg od and lisinopril 20 mg od; amlodipine 5 mg od and chlorthalidone 25 mg od; lisinopril 20 mg od and chlorthalidone 25 mg od; amiloride 10 mg od and chlorthalidone 25 mg od), 4-period crossover, lasting 32 weeks. Equal numbers of 3 ethnic groups (white, black/black British, and Asian/Asian British) will ultimately be recruited to each of the trial arms (ie, 220 participants per ethnic group per arm). Seated, automated, unattended, office, systolic blood pressure measured 8 weeks after each treatment period begins will serve as the primary outcome measure.
CONCLUSION: AIM-HY INFORM is a prospective, open-label, randomized trial which aims to evaluate first- and second-line antihypertensive therapies for multiethnic populations.
|Journal Article Type||Article|
|Publication Date||Oct 1, 2018|
|Journal||American Heart Journal|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Mukhtar, O., Cheriyan, J., Cockcroft, J. R., Collier, D., Coulson, J. M., Dasgupta, I., …Wilkinson, I. B. (2018). A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: the comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial. American Heart Journal, 204, 102-108. https://doi.org/10.1016/j.ahj.2018.05.006|
|Keywords||Cardiology and Cardiovascular Medicine|
A randomized controlled crossover trial
You might also like
Hypertension in adults: summary of updated NICE guidance
Clinical and molecular features of thiazide-induced hyponatremia
Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia